BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress

Victoria Roulstone, Malin Pedersen, Joan Kyula, David Mansfield, Aadil A. Khan, Grainne Mcentee, Michelle Wilkinson, Eleni Karapanagiotou, Matt Coffey, Richard Marais, Adel Jebar, Fiona Errington-Mais, Alan Melcher, Richard Geoffrey Vile, Hardev Pandha, Martin Mclaughlin, Kevin J. Harrington

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Reovirus type 3 (Dearing) (RT3D) infection is selective for cells harboring a mutated/activated RAS pathway. Therefore, in a panel of melanoma cell lines (including RAS mutant, BRAF mutant and RAS/BRAF wild-type), we assessed therapeutic combinations that enhance/suppress ERK1/2 signaling through use of BRAF/MEK inhibitors. In RAS mutant cells, the combination of RT3D with the BRAF inhibitor PLX4720 (paradoxically increasing ERK1/2 signaling in this context) did not enhance reoviral cytotoxicity. Instead, and somewhat surprisingly, RT3D and BRAF inhibition led to enhanced cell kill in BRAF mutated cell lines. Likewise, ERK1/2 inhibition, using the MEK inhibitor PD184352, in combination with RT3D resulted in enhanced cell kill in the entire panel. Interestingly, TCID 50 assays showed that BRAF and MEK inhibitors did not affect viral replication. Instead, enhanced efficacy was mediated through ER stress-induced apoptosis, induced by the combination of ERK1/2 inhibition and reovirus infection. In vivo, combined treatments of RT3D and PLX4720 showed significantly increased activity in BRAF mutant tumors in both immune-deficient and immune-competent models. These data provide a strong rationale for clinical translation of strategies in which RT3D is combined with BRAF inhibitors (in BRAF mutant melanoma) and/or MEK inhibitors (in BRAF and RAS mutant melanoma).

Original languageEnglish (US)
Pages (from-to)931-942
Number of pages12
JournalMolecular Therapy
Volume23
Issue number5
DOIs
StatePublished - May 9 2015

Fingerprint

Mammalian orthoreovirus 3
Mitogen-Activated Protein Kinase Kinases
Melanoma
Reoviridae Infections
Cell Line
Apoptosis
Infection

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Roulstone, V., Pedersen, M., Kyula, J., Mansfield, D., Khan, A. A., Mcentee, G., ... Harrington, K. J. (2015). BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Molecular Therapy, 23(5), 931-942. https://doi.org/10.1038/mt.2015.15

BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. / Roulstone, Victoria; Pedersen, Malin; Kyula, Joan; Mansfield, David; Khan, Aadil A.; Mcentee, Grainne; Wilkinson, Michelle; Karapanagiotou, Eleni; Coffey, Matt; Marais, Richard; Jebar, Adel; Errington-Mais, Fiona; Melcher, Alan; Vile, Richard Geoffrey; Pandha, Hardev; Mclaughlin, Martin; Harrington, Kevin J.

In: Molecular Therapy, Vol. 23, No. 5, 09.05.2015, p. 931-942.

Research output: Contribution to journalArticle

Roulstone, V, Pedersen, M, Kyula, J, Mansfield, D, Khan, AA, Mcentee, G, Wilkinson, M, Karapanagiotou, E, Coffey, M, Marais, R, Jebar, A, Errington-Mais, F, Melcher, A, Vile, RG, Pandha, H, Mclaughlin, M & Harrington, KJ 2015, 'BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress', Molecular Therapy, vol. 23, no. 5, pp. 931-942. https://doi.org/10.1038/mt.2015.15
Roulstone, Victoria ; Pedersen, Malin ; Kyula, Joan ; Mansfield, David ; Khan, Aadil A. ; Mcentee, Grainne ; Wilkinson, Michelle ; Karapanagiotou, Eleni ; Coffey, Matt ; Marais, Richard ; Jebar, Adel ; Errington-Mais, Fiona ; Melcher, Alan ; Vile, Richard Geoffrey ; Pandha, Hardev ; Mclaughlin, Martin ; Harrington, Kevin J. / BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. In: Molecular Therapy. 2015 ; Vol. 23, No. 5. pp. 931-942.
@article{5e6b22eb22ee43faad9b71483b5ca71e,
title = "BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress",
abstract = "Reovirus type 3 (Dearing) (RT3D) infection is selective for cells harboring a mutated/activated RAS pathway. Therefore, in a panel of melanoma cell lines (including RAS mutant, BRAF mutant and RAS/BRAF wild-type), we assessed therapeutic combinations that enhance/suppress ERK1/2 signaling through use of BRAF/MEK inhibitors. In RAS mutant cells, the combination of RT3D with the BRAF inhibitor PLX4720 (paradoxically increasing ERK1/2 signaling in this context) did not enhance reoviral cytotoxicity. Instead, and somewhat surprisingly, RT3D and BRAF inhibition led to enhanced cell kill in BRAF mutated cell lines. Likewise, ERK1/2 inhibition, using the MEK inhibitor PD184352, in combination with RT3D resulted in enhanced cell kill in the entire panel. Interestingly, TCID 50 assays showed that BRAF and MEK inhibitors did not affect viral replication. Instead, enhanced efficacy was mediated through ER stress-induced apoptosis, induced by the combination of ERK1/2 inhibition and reovirus infection. In vivo, combined treatments of RT3D and PLX4720 showed significantly increased activity in BRAF mutant tumors in both immune-deficient and immune-competent models. These data provide a strong rationale for clinical translation of strategies in which RT3D is combined with BRAF inhibitors (in BRAF mutant melanoma) and/or MEK inhibitors (in BRAF and RAS mutant melanoma).",
author = "Victoria Roulstone and Malin Pedersen and Joan Kyula and David Mansfield and Khan, {Aadil A.} and Grainne Mcentee and Michelle Wilkinson and Eleni Karapanagiotou and Matt Coffey and Richard Marais and Adel Jebar and Fiona Errington-Mais and Alan Melcher and Vile, {Richard Geoffrey} and Hardev Pandha and Martin Mclaughlin and Harrington, {Kevin J.}",
year = "2015",
month = "5",
day = "9",
doi = "10.1038/mt.2015.15",
language = "English (US)",
volume = "23",
pages = "931--942",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress

AU - Roulstone, Victoria

AU - Pedersen, Malin

AU - Kyula, Joan

AU - Mansfield, David

AU - Khan, Aadil A.

AU - Mcentee, Grainne

AU - Wilkinson, Michelle

AU - Karapanagiotou, Eleni

AU - Coffey, Matt

AU - Marais, Richard

AU - Jebar, Adel

AU - Errington-Mais, Fiona

AU - Melcher, Alan

AU - Vile, Richard Geoffrey

AU - Pandha, Hardev

AU - Mclaughlin, Martin

AU - Harrington, Kevin J.

PY - 2015/5/9

Y1 - 2015/5/9

N2 - Reovirus type 3 (Dearing) (RT3D) infection is selective for cells harboring a mutated/activated RAS pathway. Therefore, in a panel of melanoma cell lines (including RAS mutant, BRAF mutant and RAS/BRAF wild-type), we assessed therapeutic combinations that enhance/suppress ERK1/2 signaling through use of BRAF/MEK inhibitors. In RAS mutant cells, the combination of RT3D with the BRAF inhibitor PLX4720 (paradoxically increasing ERK1/2 signaling in this context) did not enhance reoviral cytotoxicity. Instead, and somewhat surprisingly, RT3D and BRAF inhibition led to enhanced cell kill in BRAF mutated cell lines. Likewise, ERK1/2 inhibition, using the MEK inhibitor PD184352, in combination with RT3D resulted in enhanced cell kill in the entire panel. Interestingly, TCID 50 assays showed that BRAF and MEK inhibitors did not affect viral replication. Instead, enhanced efficacy was mediated through ER stress-induced apoptosis, induced by the combination of ERK1/2 inhibition and reovirus infection. In vivo, combined treatments of RT3D and PLX4720 showed significantly increased activity in BRAF mutant tumors in both immune-deficient and immune-competent models. These data provide a strong rationale for clinical translation of strategies in which RT3D is combined with BRAF inhibitors (in BRAF mutant melanoma) and/or MEK inhibitors (in BRAF and RAS mutant melanoma).

AB - Reovirus type 3 (Dearing) (RT3D) infection is selective for cells harboring a mutated/activated RAS pathway. Therefore, in a panel of melanoma cell lines (including RAS mutant, BRAF mutant and RAS/BRAF wild-type), we assessed therapeutic combinations that enhance/suppress ERK1/2 signaling through use of BRAF/MEK inhibitors. In RAS mutant cells, the combination of RT3D with the BRAF inhibitor PLX4720 (paradoxically increasing ERK1/2 signaling in this context) did not enhance reoviral cytotoxicity. Instead, and somewhat surprisingly, RT3D and BRAF inhibition led to enhanced cell kill in BRAF mutated cell lines. Likewise, ERK1/2 inhibition, using the MEK inhibitor PD184352, in combination with RT3D resulted in enhanced cell kill in the entire panel. Interestingly, TCID 50 assays showed that BRAF and MEK inhibitors did not affect viral replication. Instead, enhanced efficacy was mediated through ER stress-induced apoptosis, induced by the combination of ERK1/2 inhibition and reovirus infection. In vivo, combined treatments of RT3D and PLX4720 showed significantly increased activity in BRAF mutant tumors in both immune-deficient and immune-competent models. These data provide a strong rationale for clinical translation of strategies in which RT3D is combined with BRAF inhibitors (in BRAF mutant melanoma) and/or MEK inhibitors (in BRAF and RAS mutant melanoma).

UR - http://www.scopus.com/inward/record.url?scp=84929048574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929048574&partnerID=8YFLogxK

U2 - 10.1038/mt.2015.15

DO - 10.1038/mt.2015.15

M3 - Article

C2 - 25619724

AN - SCOPUS:84929048574

VL - 23

SP - 931

EP - 942

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -